Analyzing the Data From the ERADICATE Trial of Ceftobiprole vs Daptomycin in Complicated Staphylococcus aureus Bacteremia

The ERADICATE trial was a randomized, controlled study designed to compare ceftobiprole with daptomycin in adults with complicated Staphylococcus aureus bacteremia, including both MRSA and MSSA infections. The study focused on patients with more severe or deep-seated disease rather than simple, short-course infections such as uncomplicated line-related bacteremia.

Patients were eligible if they were 18 years or older and had either confirmed or strongly suspected complicated Staphylococcus aureus bacteremia. Importantly, enrollment and randomization occurred within 72 hours of a positive blood culture, ensuring that participants were captured early in the course of their infection. Participants were then randomized to receive either intravenous ceftobiprole or daptomycin, the latter given at standard FDA-approved dosing with flexibility for higher dosing based on institutional practice. A subset of patients in the daptomycin arm could also receive adjunct therapy (or placebo in the blinded arm) if there was concern for concurrent gram-negative infection, though this was not intended to affect treatment of Staphylococcus aureus itself.

The primary endpoint was a composite test-of-cure outcome assessed at 70 days (10 weeks) after randomization. Treatment success required survival, resolution of infection signs and symptoms, no relapse or new complications, and no use of disallowed non-study antibiotics that could confound outcomes.

The trial used a non-inferiority design because the goal was not to prove that ceftobiprole was superior to an established standard like daptomycin, but rather to demonstrate that it was not meaningfully worse while potentially offering important clinical advantages. In infectious diseases, this approach is common when evaluating new antibiotics, since even older agents like daptomycin remain effective but may not cover all resistance patterns or clinical scenarios. A non-inferiority framework allows researchers to confirm that a new therapy preserves similar efficacy while expanding treatment options in a field where bacterial resistance continues to evolve.

Overall, the ERADICATE trial was structured to determine whether ceftobiprole could safely and effectively stand alongside current standard-of-care therapy, potentially broadening the armamentarium for a high-mortality infection.

Disclaimer: Holland was the Chair of Adjudication for the ERADICATE trial.

This video series has been produced independently by Contagion Live and supported through a educational grant by Innoviva Specialty Therapeutics inc